Apellis Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Apellis Pharmaceuticals

01/11/2023 13:32

* Apellis Pharmaceuticals Inc  APLS.OQ  reported a quarterly
adjusted loss of $1.17​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of $-1.75.  The mean expectation of
fourteen analysts for the quarter was for a loss of 86 cents per
share. Wall Street expected results to range from $-1.15 to 88
cents per share.
    * Revenue rose 400.5% to $110.40 million from a year ago;
analysts
expected $99.05 million. 
    * Apellis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.17​.
    * The company reported a quarterly loss of $140.24 million.
    * Apellis Pharmaceuticals Inc shares had risen by 27.9% this
quarter and lost 5.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 26.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Apellis
Pharmaceuticals Inc is $70.00 
This summary was machine generated from LSEG data November 1 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.86          -1.17          Missed
 Jun. 30 2023      -1.32          -1.02          Beat
 Mar. 31 2023      -1.46          -1.56          Missed
 Dec. 31 2022      -1.57          -1.50          Beat